Read our latest advice on Coronavirus (COVID-19)


Our services are open and safe to attend – we are here to help

Goodman, Anna – consultant in infectious diseases and general medicine

Consultant profiles

Anna Goodman, consultant in infectious diseases and general medicine

Contacts

Tel: 020 7188 3148

Areas of expertise: COVID-19 vaccines, clinical trials in infection, community-acquired bacterial infections, malaria, S. aureus bacteraemia, Candida, imaging in infection

  • Biography

    Anna Goodman is a consultant in infectious diseases and general (internal) medicine. She has been a consultant at Guy's and St Thomas' since 2014 and also works at the MRC clinical trials unit at UCL as an associate professor. Anna runs a general infectious diseases clinic on Thursday afternoons. She also supports a dermatology/infectious diseases specialist clinic.

    Anna specialises in clinical trials in infectious diseases. She has been the local principal investigator for a number of vaccine trials in malaria and more recently COVID-19.

    Anna trained in medicine at Oxford University and the University of London.

  • Education and training

    • DPhil
    • MRCP (infectious diseases)
    • FRCP
    • FRCPath
    • DipHIV
    • DTM&H
    • MA (Oxon)
    • MBBS (Oxford University and University College London)

  • Specialist interests

    • Vaccines and COVID-19
    • Community-acquired bacterial infections

    • Fungal and parasite infections

    • Specialist infectious dermatology e.g. cutaneous leishmaniasis and non-tuberculous mycobacterial infection

  • Research interests

    • Vaccines and COVID-19
    • Vaccines and malaria
    • Imaging and infection

    • Staphylococcus aureus (S. aureus) bacteraemia

    • Antibiotic selection, duration and usage in infection

  • Publications

    Key recent publications

    Treatment of methicillin-resistant Staphylcoccus aureus (MRSA): updated guidelines from the UK J Antimicrobial Chemo in press

    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Voysey et al.  Lancet 8th Dec 2020

    Remdesivir for the Treatment of Covid-19 — N Engl J Med 2020; 383:1813-1826

    Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 391(10121):668-678